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Abstract
Catatonia is a common syndrome that was first described in the literature by Karl Kahlbaum in
1874. The literature is still developing and remains unclear on many issues, especially classification,
diagnosis, and pathophysiology. Clinicians caring for psychiatric patients with catatonic syndromes
continue to face many dilemmas in diagnosis and treatment. We discuss many of the common
problems encountered in the care of a catatonic patient, and discuss each problem with a review
of the literature. Focus is on practical aspects of classification, epidemiology, differential diagnosis,
treatment, medical comorbidity, cognition, emotion, prognosis, and areas for future research in
catatonic syndromes.
Background
Catatonic syndromes embody the practice of psychiatry as
well as any other psychiatric diagnosis. Catatonia presents
commonly in psychiatric patients in both acute and long-
term settings. Despite its common occurrence, catatonia
remains a poorly understood, poorly studied, and poorly-
recognized syndrome, presenting with a variety of psychi-
atric and medical illnesses, which can be treatable once a
diagnosis is established. Difficulties in the clinical concep-
tualization and management of catatonia have been
called "the catatonic dilemma" [1]. Theoretically, how to
organize our approach to catatonia remains disputed [2].
Many areas of overlap make the presentation unclear.
Even seasoned clinicians do not recognize the often com-
plex presentations of catatonia. The addition or with-
drawal of treatments, such as antipsychotic medications,
often complicate the clinical picture. As such, many ques-
tions in the day to day management of patients persist.
Practical social and ethical concerns also interfere with
effective treatment at times. The more we learn about cat-
atonia, the more the catatonic dilemma seems to expand.
We propose some approaches to detection, classification,
and treatment of catatonic syndromes.
Classification
Since its original description by Karl Kahlbaum in 1874,
catatonia has been discussed in the literature and is still
actively debated [3]. The DSM-IV TR concept of catatonia,
as well as other descriptions, can be confusing as they
include some seemingly contradictory clinical signs [2,4].
Motor immobility is described along with excessive motor
activity, negativism along with automatic obedience and
echopraxia, and mutism along with verbigeration and
echolalia. Also, at least forty separate signs of catatonia
have been described [2,5]. The reason for this appears to
be due to catatonia's truly variable presentation. Peralta et
al. found a significant correlation of the excited and
retarded motor symptoms, but neither correlated well
with psychosis [6]. Some argue that based on the rule of
parsimony (Occam's Razor), all of these variable presen-
tations fit into the same category [5]. However, it remains
possible that what we now discuss as catatonia may be a
nonspecific collection of various illnesses [7,8].
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The concept of catatonia has been categorized in various
manners related to clinical presentation [2,5]. Catatonia
has been conceptualized as chronic or acute, or as isolated
acute episodes versus chronic recurrent or periodic catato-
nia [5,7,9-13]. Catatonia has been divided into retarded
and excited forms, the latter often associated with signifi-
cant progression and morbidity [5,14]. Catatonia has
been described in terms of prognosis [2,15]. Catatonia has
also been discussed as an independent syndrome versus
associated with other psychiatric, neurological, and med-
ical illnesses [2,4,6,8,9,16-18]. Some view catatonia as a
"common functional final pathway" in expression of
severe neuropsychiatric illness [8]. Taylor and Fink have
more recently proposed a classification scheme dividing
catatonia into nonmalignant, delirious, and malignant
forms, with qualifiers for related illnesses [2]. DSM-IV TR
criteria currently requires only two signs, and catatonia is
not classified as a separate disorder [4]. A more unified
and separate DSM diagnostic criteria set for catatonia will
certainly aid in our understanding of its phenomenology,
subtypes, comorbidities, natural history, neurophysiol-
ogy, treatment, and prognosis. A DSM-V classification will
also increase psychiatrists' recognition of this common
condition, and stimulate further research.
Epidemiology
One problem in the epidemiologic study of catatonia is
that catatonic signs can not be elicited simply by a struc-
tured clinical interview, thus it may be under-represented
in population samples. Historically, prevalence rates for
catatonia have been recorded between 6% and 38% for
acute psychotic episodes, and only about 7% to 17% of
those patients meet criteria for catatonic schizophrenia
[2,5,13]. Catatonic schizophrenia has been reported at a
rate of 1 in 1000 in the general population, and up to 5%
of all new diagnoses of schizophrenia [11]. Heterogene-
ous study samples have led to catatonia being described as
rare in schizophrenia, and alternately in another study
32% of 225 chronic inpatient schizophrenics met a nar-
row definition for catatonia [7,18]. Guggenheim and
Babigian found that 13% of schizophrenic admissions at
a state hospital were of the catatonic subtype, while only
3% of those at a university hospital were catatonic, with a
community hospital at an intermediate value [11]. How-
ever, multiple other studies of rates of chronic catatonic
schizophrenia at single sites, with unchanged definitions
over time, show the incidence has decreased significantly
(decreases range from 34.2% to 91.7%) over time inter-
vals that correlate with the introduction of neuroleptics
[19]. More recently catatonia is described as having a
lower incidence of 2% to 8% of acute admissions [8].
Interestingly, the rates for periodic catatonia have
remained relatively stable [19]. Thus, decreased incidence
of catatonia is not fully explained by changing definitions.
Other proposed explanations include improved nursing
and social regimes, decreased incidence of viral epidemics
coupled with the dying out of a cohort of patients with
encephalitis lethargica, a decreased interest by psychia-
trists in motor symptoms, and van der Heijden and col-
leagues have advocated that we are simply under-
diagnosing catatonia [18,20-22]. Catatonic symptoms
have also been found often in groups of affective disor-
dered patients at rates ranging from 13% to 31%, espe-
cially in manic-depressives [2,19,23]. In fact, catatonic
signs are not specific to any disorder, and are seen in psy-
chotic disorders, bipolar disorders, depressive disorders,
reactive disorders, conversion disorders, dementias, other
organic disorders, and without identifiable underlying
pathology [8,19]. An accepted and consistent diagnostic
scheme for catatonic syndromes will certainly aid in the
delineation of their epidemiology.
Differential diagnosis
The differential diagnosis in catatonia in psychiatric and
medical patients can be challenging, and remains a prob-
lem for clinicians [9,21]. It is a common occurrence for
cases reported in the literature to have the specifics of their
diagnosis contested. The differential diagnosis of catato-
nia involves three parts: (a) recognizing the distinct clus-
ter of signs of a catatonic syndrome; (b) distinguishing
catatonia from other movement disorders, including a
range of other specific physiological and psychomotor
syndromes that may share common features; and (c)
identifying sequelae and co-morbidity with other neuro-
logic, medical, and psychiatric pathology. The following
discussion focuses mainly on identifying catatonic syn-
dromes presenting in a co-morbid manner with other
known neurologic, medical, and psychiatric illnesses.
Clinical examination
Given the variability of presentation, and multiple ways of
conceptualizing catatonia, a high index of suspicion and
broader pattern recognition is needed for the better diag-
nosis and delineation of catatonic signs and syndromes in
medical and psychiatric patients. If a clinician only has in
mind the classic description of the mute, cataleptic, rigid,
and negativistic schizophrenic they will miss many cases
of catatonia. Indeed, there is emerging evidence that cata-
tonic signs are missed in modern clinical practice [21].
Rather than a limited, and often cursory, neurological
exam, an active and thorough clinical examination should
be part of every acute psychiatric evaluation, especially
since patients may exhibit anosognosia [24,25]. Specific
catatonic signs to elicit include: complete to semi-elective
mutism, stupor, sudden intermittent excitement,
echophenomena, stimulus-bound and utilization behav-
ior, stereotypic movements, grimacing and other facial
movements, ambitendency, perseveration, mannerisms
and other speech disorders, abnormal posture, catalepsy,Annals of General Psychiatry 2006, 5:14 http://www.annals-general-psychiatry.com/content/5/1/14
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waxy flexibility, automatic obedience, and negativism
[24,26].
Neurologic and movement disorders
The ongoing debate over whether the etiology of catatonic
syndromes are best understood as psychological or as
neurological (e.g., movement disorders) in origin, and
complicated by neuroleptic treatment and hospitaliza-
tion, has been termed a "conflict of paradigms" [8,27,28].
Some advocate viewing catatonia as a form of "psychomo-
tor" disturbance or movement disorder, and since various
movement disorders can present similarly, they place
emphasis on precise description of motor abnormalities
[7,8,28]. Catatonia's immobility, negativism, and waxy
flexibility may share features of parkinsonism's bradyki-
nesia and stiffness. Catatonia has many symptoms that
overlap with parkinsonism, and cases have been reported
of both together [8,9,27,29-31]. Clouding the picture is
the use of antipsychotics in the treatment of psychotic dis-
orders. The extrapyramidal side effects of antipsychotics
have the same potential for confusion with catatonia as
parkinsonism [8,18]. Elderly patients and those with
degenerative neurological diseases may present with
spontaneous movement disorders, which may be mis-
taken for catatonia [32,33]. Catatonia shares enough fea-
tures of neuroleptic malignant syndrome (NMS) that
many have examined their relationship [5,34-37]. Distin-
guishing catatonia from other similar syndromes – malig-
nant hyperthermia, NMS, toxic serotonin syndrome, stiff-
person syndrome, locked-in syndrome, hypocalcemia,
tetanus, strychnine toxicity, rabies, and elective mutism –
has been well-described in the literature [2,5,26,38].
Delirium
Catatonia presents commonly in medical settings. Similar
to catatonia, delirium has also been described as hypoac-
tive and hyperactive [39,40]. Catatonia can have a waxing
and waning presentation, alternating between retardation
and excitement, and involve stupor or a change in the
level of consciousness [41]. Diagnosis can become diffi-
cult, especially in cases with both stupor and mutism, and
we need better distinctions [16]. This distinction is partic-
ularly important in terms of treatment. Electroconvulsive
therapy (ECT) and benzodiazepines can be useful in the
treatment of both catatonia and certain forms of delirium,
but both may also produce or exacerbate delirium [42-
44]. Conversely, antipsychotics used to treat symptoms of
delirium have the potential to produce or exacerbate
motor signs and catatonia [44-48]. Regardless, a compre-
hensive evaluation for potential medical causes should be
performed in suspected cases of both delirium and catato-
nia. Underlying medical issues should be addressed for
both. With the exception of epileptiform catatonia, rela-
tively normal electroencephalogram and reflex functions
may help distinguish catatonic stupor from delirium [49].
In most cases, the diagnosis of delirium will take prece-
dence, and symptoms will gradually clear with treatment
of underlying medical illness, and environmental and
pharmacologic interventions. In medical catatonia, treat-
ment of the underlying condition commonly does not
result in resolution of catatonic symptoms. Therefore, in
cases with continued stupor or other catatonic signs, with
no clear metabolic, pharmacologic, neurologic or other
medical explanation, a diagnosis of catatonia should be
considered heavily. At this point, the risk-benefit ratio
often favors treatment with a brief trial of benzodi-
azepines or ECT. We discuss medical co-morbidity and
sequelae in more detail later.
Psychiatric illness
Similarly, catatonic syndromes often present comorbidly
with psychiatric disorders. The periodicity of recurrent cat-
atonic episodes can be reminiscent of bipolar cycling, and
others have described a separate entity of confusional
cycloid psychosis [6,50-52]. Delirious mania may appear
similar to catatonia [37,53]. Also, patients with catatonic
excitement may appear hypomanic or manic, though typ-
ically with fewer mood symptoms, and more idiosyncratic
motor symptoms [54,55]. Some suggest that the presence
of catatonic excitement indicates an underlying bipolar
disorder [2]. Repetitive mannerisms of catatonia may phe-
nomenologically overlap with obsessive-compulsive
symptoms, but the relationship is unclear [18,56,57]. The
seemingly volitional nature of negativism can make one
question the possibility of malingering, or possibly con-
version disorder, if not for the remainder of the clinical
presentation.
Schizophrenia
A common occurrence in clinical practice is the diffuse
and often cavalier use of the diagnosis "chronic paranoid
schizophrenia," even amongst trained psychiatrists. This
may lead to under-recognition of clinically important cat-
atonic signs in subsequent episodes. It is not uncommon
for catatonic schizophrenics to be given other subtype
diagnoses during their clinical course, especially of the
paranoid subtype [11]. Though this suggests catatonia
occurs in relation to schizophrenic episodes and illness, it
also allows for the possibility it may be an independent
process. Diagnostic subcategories of schizophrenia may
be disputed, but were developed with great thoughtful-
ness, and for a purpose. They are useful not only in com-
munication between clinicians, but have proven helpful
in determining potential treatment choices, and progno-
sis. If a patient clearly has persistent or recurring episodes
of catatonia in addition to other psychotic symptoms, the
diagnosis of catatonic schizophrenia should be made. The
catatonic subtype of schizophrenia in particular has spe-
cific treatments that have proven effective, which also sug-
gests it may be a separate entity requiring a uniqueAnnals of General Psychiatry 2006, 5:14 http://www.annals-general-psychiatry.com/content/5/1/14
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treatment approach. The catatonic subtype of schizophre-
nia remains a recognized form of schizophrenia [18,58].
However, the validity of continuing to distinguish a cata-
tonic subtype of schizophrenia requires further study. A
separate diagnostic category for catatonia would aid in the
recognition and treatment of catatonic syndromes in
schizophrenia, and would not necessarily detract from the
concepts of schizophrenia.
Medical comorbidity
Medical conditions, including metabolic and nutritional
imbalances have long been associated with catatonia, and
it is generally accepted that certain medical conditions can
be causative [2,5,9,22,26,59-61]. Studies identify over 35
medical and neurological illnesses associated with catato-
nia, with those most likely to be causative including CNS
structural damage, encephalitis and other CNS infections,
seizures, metabolic disturbances, phencyclidine exposure,
neuroleptic exposure, lupus cerebritis, corticosteroids,
disulfuram, porphyria, and other conditions [61]. Medi-
cal catatonia may account for as many as 20% to 30% of
cases of catatonia [61]. Distinguishing whether an associ-
ated physical finding is a cause or result of catatonia is a
difficult process. Many of the findings associated with cat-
atonia may also be a marker for another process, such as
poor nutrition or other complications.
Laboratory and imaging
Multiple laboratory findings are of interest in catatonic
patients, but caution must be exercised in interpreting
most of these study results as they are necessarily method-
ologically limited. Intermittent shifts in nitrogen balance,
measured via blood urea nitrogen and urine ammonia or
urea, speculatively related to retention of a noxious meta-
bolic substance, have been found to rhythmically corre-
spond to periodic catatonia [62]. Low serum iron and
calcium metabolism have been associated with acute or
malignant catatonia, especially neuroleptic malignant
syndrome (NMS) [63-67]. Elevated white blood cell
counts and creatine phosphokinase levels are both non-
specific, though common in acute or malignant catatonia
and NMS, appear less common and intense in chronic or
simple catatonia [12,62]. Severe hyponatremia and cor-
rection has been associated with catatonia [30,31]. Vita-
min B12 deficiency has been associated with catatonia, and
supplementation has resulted in improvement of catato-
nia [68,69]. Laboratory findings suggesting CNS dysregu-
lation of dopaminergic, noradrenergic, and possibly
cholinergic and serotoninergic systems have each been
implicated, but require further study along with other
neurotransmitters [62]. More recent functional neuroim-
aging studies have supported the role of the gamma-
amino butyric acid (GABA) and glutamatergic (via
NMDA-receptors) systems in catatonia [8]. Computed
tomography studies in catatonic patients have reported
cortical enlargement and cerebellar atrophy, but no con-
sistently specific findings [8].
Medical sequelae
Medical complications are common in catatonia, even
"benign" catatonia [22,60,70]. Psychotic and other men-
tally ill patients often have unhealthy lifestyles, may be
unable to care properly for their medical conditions, and
are at an increased risk for developing various complica-
tions [71,72]. Another common clinical concern is that
catatonic behavior can mask signs and symptoms of seri-
ous underlying medical conditions, necessitating vigi-
lance in ongoing physical evaluation of catatonic patients
[11]. Patients with catatonic disorders who are unable to
care for their own medical problems are often neglected in
chronic institutionalized settings. Chronic catatonic
patients are at increased risk for developing aspiration,
pulmonary embolus, drug-resistant infections, dehydra-
tion, malnutrition necessitating enteral feeding, constipa-
tion, contractures, skin breakdown, poor dentition, poor
menstrual hygiene, urinary retention and bladder infec-
tions [73]. Prophylactic measures should be carefully con-
sidered as they often put the patient at risk for other
complications. There is a continued need to develop treat-
ment methods, beyond partial response in catatonia and
schizophrenia, to improve the quality of life for our
patients.
Cognition, emotion and behavior
Phenomenology
The complex interactions between cognition, emotion
and behavior in catatonia will eventually lead to better
understanding of its etiology. Kahlbaum's original con-
ception described catatonia as part of generally deteriorat-
ing mental process [22,74]. Defective memory was
common (56 of 214) in another large sample of catatonic
schizophrenics [15]. Catatonia has been reported to result
in lasting cognitive impairment [75]. Neuropsychological
testing on recently recovered catatonic patients has pre-
liminarily revealed intact general intelligence, attention
and executive functions, deficits in right parietal visuo-
spatial function and emotionally guided intuitive deci-
sions on gambling tasks, and disturbed constructs of
"self" [8]. Phenomenologically, recovered catatonic
patients usually describe having experienced intense emo-
tional states, often uncontrollable anxiety and over-
whelming fear, but also ambivalence, depression,
euphoria, lability, aggression and psychosis [8,76]. Motor
signs are common in patients with psychotic, mood and
anxiety disorders, but behavior and motor disturbances in
catatonic patients may be our only evidence to guide diag-
nostic and treatment decisions [26,77]. Frequently cata-
tonics remain unaware of their behavioral and motor
signs, reporting that they were functioning normally. Cat-
atonic patients may exhibit behavior that appears con-Annals of General Psychiatry 2006, 5:14 http://www.annals-general-psychiatry.com/content/5/1/14
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sciously produced, though many of the cognitive
processes reflected in catatonic behavior likely occur
unconsciously [78].
Recent theories
As a complex psychomotor syndrome, catatonia has been
conceptualized by Northoff as a predominantly a cortical
process dynamically interacting with subcortical regions,
involving cognitive, emotional, and behavioral circuits
[8,79,80]. Northoff distinguishes catatonia from parkin-
sonism and NMS, which he describes as mainly subcorti-
cal syndromes [80]. Northoff hypothesizes that, in
catatonic patients, alterations primarily in orbitofrontal
and right posterior parietal functioning may modulate
other cortical structures responsible for cognition, affect,
and behavior, as well as subcortical structures responsible
for movement [79,80]. A hyperdopaminergic mesolimbic
system may attempt a restitutive downregulation of
dopamine to ward off psychosis, thus affecting other sys-
tems, and producing motor symptoms via the nigrostri-
atal pathway [62,81]. Involvement of the anterior
cingulate, amygdala, hippocampi, thalamic nuclei and
basal ganglia are possible. Fricchione also conceptualizes
catatonia in a complex network model of neurocircuits
and loops at various levels, hypothesizing a disorder of
basal ganglia thalamo(limbic)-cortical circuits [81]. How-
ever, Fricchione focuses on explaining catatonia in terms
the evolution of structures and circuits responsible for
mammalian social behavior, specifically attachment-sep-
aration adaption strategies [81]. Catatonic syndromes
may represent a regression to or neurological vestige of
more primitive mechanisms, modulating disinhibited
confrontation versus freezing strategies for dealing with
threat, which would necessarily be linked to intense emo-
tions [76,78,81,82]. These models allow for production of
catatonic signs and syndromes from dysfunction of vari-
ous neurotransmitter systems or neurological lesions. To
further explore these issues, a consensus is needed on how
to best measure and approach both cognition and affect in
catatonic patients, who are by the nature of their illness
limited in their ability to cooperate and report symptoms.
Treatment
Benzodiazepines
An initial trial of pharmacotherapy is often possible and
preferable in catatonic patients. Historically, a trial of
sodium amytal was recommended [83]. More recently,
benzodiazepines, especially lorazepam from modest to
high doses, have been widely studied and used in the
treatment of the various forms of catatonia, but most
studies are small and have methodological shortcomings
[2,84-87]. Though this has been proven to be a good treat-
ment on average, the degree of symptom response for
individual patients may vary tremendously. At least one
clinical trial has suggested that lorazepam may not be effi-
cacious in the treatment of chronic catatonia [88].
Another concern with use of benzodiazepines in the case
of poor or non-response is that catatonia has also been
reported with benzodiazepine withdrawal [89,90]. Thus,
a trial of a benzodiazepine such as lorazepam to test for
response should be attempted, especially in the retarded
form of catatonia, but if there is no initial response at an
adequate dose the trial should be kept brief to avoid inter-
ference with ECT and the possibility of exacerbating the
syndrome via withdrawal. Earlier consideration of ECT
could avert such a dilemma.
Antipsychotics and other medications
The question remains whether or not to use antipsychot-
ics in catatonia, especially newer agents in nonmalignant
catatonic patients with a history of psychosis or diagnosis
of a psychotic disorder [45]. A concern is causing worsen-
ing in symptomatology with neuroleptic treatment, or
clouding the clinical picture with parkinsonism [34,46-
48,91,92]. Antipsychotics have been reported to cause
neuroleptic-induced catatonia [46,48]. Antipsychotics,
even the atypicals, are known to induce neuroleptic malig-
nant syndrome in catatonic patients [9,46,93-95]. One
study found no correlation between antipsychotic dose
and severity of catatonia [18]. However, rates of catatonic
schizophrenia have decreased since the introduction of
neuroleptics [19]. Psychotropics that have been suggested
and studied in the treatment of catatonia – including cloz-
apine, other atypical antipsychotics, anticonvulsants, lith-
ium, amantadine and others – have shown variable
degrees of success [8,96-101]. Variable response may
reflect responses to the wide array of comorbid conditions
seen with catatonic syndromes more than a specific effect
on catatonia itself. If catatonia is to be viewed as a distinct
syndrome that may be comorbid and interact with other
disorders, concomitant treatment of syndromes should be
attempted. It is reasonable to attempt a concomitant trial
of atypical antipsychotics if the patient has a history of
chronic psychotic illness or exhibits psychotic signs or
symptoms in addition to catatonic signs. Avoid higher
potency antipsychotics, and monitor closely for adverse
effects, especially NMS. Similarly, a trial of an antidepres-
sant or mood stabilizer treatment would be indicated for
catatonia in the setting of a mood episode or disorder.
Electroconvulsive therapy
Clinicians are often left with the question of what to do in
the case of poor to partial response to initial pharmaco-
logical treatment. Though some report the high response
rates of catatonia, partial responses to benzodiazepine
therapy is common, especially in catatonic schizophrenia
[5,9]. Always reconsider the diagnosis. ECT is considered
the ultimate treatment for catatonia, especially resistant
forms [8,42,43]. ECT has been shown effective in the
treatment in cases of prolonged catatonia, even those par-Annals of General Psychiatry 2006, 5:14 http://www.annals-general-psychiatry.com/content/5/1/14
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tially responsive to pharmacologic treatments [102,103].
Poor nutrition and other complications are often the
deciding factors in whether to pursue ECT or not. How-
ever, practical, cultural, ethical and legal considerations
determine how far to push for such treatment, and
patients or guardians are often reluctant to consent to
ECT, despite education [104-106]. Because of the stigma
and past abuses, and remaining controversy about poten-
tial adverse effects, there are multiple legal and ethical bar-
riers to the use of ECT, which can be frustrating to
providers who wish to provide a treatment known to be
safe and effective for patients with grave disability due to
catatonia [107]. Each decision must be tailored to the
individual patient's situation. Regardless, given its effec-
tiveness and tolerability, clinicians should advocate early
for acceptance of ECT treatment in cases of catatonia.
Psychosocial treatments
Despite a history of being viewed by Kraepelin and Bleuler
as originating from psychic factors, or by others as a social
construct, there is currently a dearth of information on
practical psychosocial and environmental treatments in
catatonic syndromes [8,22,28]. In fact, some have argued
that interventions such as hospitalization may worsen cat-
atonia [28]. Catatonia is now viewed by most clinicians in
a predominantly biologic framework. We do not know
the possible role of intense emotional states in perpetuat-
ing or predisposing to catatonia. However, a more com-
plete biopsychosocial model has been helpful in
understanding and treating catatonia [76,108]. Though
purely psychoanalytic treatments may be considered
failed attempts by many, their contribution to the field is
undeniable [22]. More recent neuroanatomic theories in
many ways parallel earlier psychoanalytic theories
[78,82]. Psychological and social interventions should
complement biological treatments, and may have particu-
lar utility as an adjunct in cases of chronic catatonia, or in
those with poor treatment response. Certainly, we need
more research in this area.
Treatment response
Catatonia remains a clinical diagnosis. Thus, treatment
response may be difficult to objectively measure. Though
typically less well-validated or specific to a co-morbid dis-
order, after diagnosis is established, briefer versions of rat-
ing scales can be useful clinically in monitoring treatment
response in patients with catatonia [109-111]. Of these,
the Bush Francis Catatonia Rating Scale is currently the
most sensitive and best validated rating instrument for
broad clinical use with acute catatonic patients [109]. One
should also consider the Rogers catatonia scale for use in
patients with depressive and other mood disorders [110].
Also, consider monitoring creatine phosphokinase levels
in cases of acute catatonia.
Prognosis
From the earliest descriptions of catatonia it was noted to
have an extremely variable prognosis, ranging from good
recovery to acute onset with rapid progression to death
(often complicated by renal failure) [73]. Most likely, the
greatest factor in determining prognosis in a catatonic
syndrome is the nature and severity of comorbid or under-
lying conditions [73]. Studies thus reflect that prognosis
in catatonic syndromes may in part depend on the defini-
tion used, and opinions differ widely [112]. In Kahl-
baum's syndrome, which also included mood episodes,
prognosis was better than for schizophrenia [6]. Recurrent
or periodic catatonia has been associated with a very good
prognosis [73]. Affective and alcohol use disorders, as
well as diagnosis with a reactive psychosis or acute illness,
have been shown predictive of better response [15,112].
Relationship of specific motor symptoms to response
rates has been examined in catatonic schizophrenics, but
consistent results have not been reported in the literature
[15,23]. The presence of catatonia in schizophrenics has
been associated with earlier and greater mortality
[11,113]. Ungvari et al found a high proportion of catato-
nia among institutionalized schizophrenics [18]. Severity
of catatonia has been correlated with poorer functional
outcome [18]. Levenson and Pandurangi nicely reviewed
relative prognosis by associated condition from best to
worst as: mood disorder without catatonia, depression
with catatonia, periodic catatonia, cycloid psychoses with
catatonia, bipolar disorder with catatonia, catatonic schiz-
ophrenia, then non-catatonic schizophrenia [73].
Another factor that affects prognosis is which treatments
are used, which vary across treatment settings, and have
varied throughout the years. Younger age at onset, confu-
sion and diagnosis of schizophrenia have been shown
predictive of poorer treatment response [15,112]. Some
studies suggest catatonic schizophrenia is only 40% to
50% likely to respond to benzodiazepines [9,114]. Bio-
logical markers have not yet been consistently associated
with prognosis and require further study [73].
Further study
Subsets of patients and families with specific forms of cat-
atonia have been studied since the 1950s [15]. Stöber and
colleagues discovered the first specific gene to be associ-
ated with a primary psychiatric disorder while studying
periodic catatonia [115-119]. There is some evidence that
certain patients may have a genetic predisposition to
development of neuroleptic malignant syndrome with
antipsychotic treatment during catatonia [120]. Further
genetic discoveries are inevitable. Whether catatonic signs
and behavior constitute a specific subtype of schizophre-
nia, versus separate but often comorbid conditions, needs
further study if catatonic signs are continued to be
included in the diagnostic criteria for schizophrenia. Cat-
atonic syndromes should also be included in studies ofAnnals of General Psychiatry 2006, 5:14 http://www.annals-general-psychiatry.com/content/5/1/14
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delirium. Functional neuroimaging offers promise in the
study of catatonia [79,80,121]. More neuropathologic
studies are also needed. With time, translational research
may bring more strategies for diagnosis, to help determine
response to various treatment options, and elucidate
other prognostic factors that may assist in management.
Genetic and imaging research may also lend insight into
the pathophysiology of the various clinical presentations
of catatonia, though this could take decades. Now, with
the advent of well-validated and comprehensive catatonia
rating scales, research in catatonia will have added objec-
tivity [122,123]. We especially need further developments
and controlled pharmacologic and psychosocial treat-
ment trials in all forms of catatonia. Transcranial mag-
netic stimulation (TMS) is not currently a valid treatment,
but if catatonia turns out to be a predominantly cortical
process then there may be a role for it [124,125]. Perhaps
TMS and other somatic treatments may eventually prove
beneficial in catatonia.
Conclusion
It is clear from the review of literature that we need a better
consensus and greater clarity in the diagnosis and descrip-
tion of catatonia. A high index of suspicion and broader
syndrome pattern recognition for catatonia should be
exercised by clinicians, and should include precise
description of signs. Better recognition will help us better
delineate catatonic syndromes. By expanding our nosol-
ogy with genetic and other translational basic science
research we can better understand the pathophysiology of
catatonia. A separate and more descriptive DSM-V diag-
nostic criteria set for catatonia will aid in our understand-
ing of catatonia's phenomenology, subtypes,
comorbidities, natural history, neurophysiology, treat-
ment and prognosis. An improved DSM-V classification
will also increase psychiatrists' recognition of this com-
mon syndrome, and stimulate further research. We will
likely gain better understanding of the intricacies of psy-
chotic, mood, movement, anxiety, and somatoform disor-
ders, as well as such issues as volition and will. This will
lead to delineation of prognosis, better management
choices, and ultimately to improvement in the general
medical health and quality of life of our patients. Practical
roadblocks and ethical concerns often get in the way of
treatment. We must continue to advocate for better social
acceptability of electroconvulsive therapy as a legitimate
treatment option in psychiatric and medical patients.
Meanwhile, we must continue to attend to the psycholog-
ical and social needs of catatonic patients.
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